

Guidance on Esomeprazole Magnesium

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Esomeprazole Magnesium

Form/Route: Delayed Release Capsules/Oral

Recommended studies: 3 studies

1. Type of study: Fasting
Design: Single-dose, two-way crossover *in-vivo*
Strength: 40 mg
Subjects: Normal healthy males and females, general population
Additional Comments:

2. Type of study: Fed
Design: Single-dose, two-way crossover *in-vivo*
Strength: 40 mg
Subjects: Normal healthy males and females, general population
Additional comments:

3. Type of study: Sprinkle
Design: Single-dose, two-way crossover *in-vivo*
Strength: 40 mg
Subjects: Normal healthy males and females, general population
Additional Comments: Fasting study, with treatments sprinkled over a spoonful of applesauce.

Analytes to measure: Esomeprazole using an achiral assay.

Bioequivalence based on (90% CI): Esomeprazole

Waiver request of in-vivo testing: 20 mg based on (i) acceptable bioequivalence studies on the 40 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. For dissolution method development, please refer to USP, "Delayed-Release (Enteric-Coated) Articles-General Drug Release Standard."

Esomeprazole is an acid labile drug substance; therefore, please measure esomeprazole from the beadlets of the EC capsule and not from the dissolution medium (0.1N HCl) during the acid stage. Using 12 additional capsules of the test and reference products, proceed to the buffer stage. Dissolution specifications will be determined upon review of the data in the ANDA.